Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Life Sciences
Characterizing The Effects Of 14-3-3 Isoforms On Alpha-Synuclein Toxicity In A Yeast Model, Angela Marie Braunschweiger
Characterizing The Effects Of 14-3-3 Isoforms On Alpha-Synuclein Toxicity In A Yeast Model, Angela Marie Braunschweiger
Browse all Theses and Dissertations
The presynaptic protein alpha-synuclein encoded by SNCA is the primary component of Lewy bodies and Lewy neurites which are the histopathological hallmarks of Parkinson’s disease. While the etiology of Parkinson’s remains unclear, SNCA mutations and copy number variations are one of several genes linked to Parkinson’s. The family of highly conserved chaperone proteins 14-3-3 have been shown to co-aggregate and share regions of 40% homology with alpha-synuclein. Mitochondrial dysfunction also plays a role in Parkinson’s disease with abnormalities in mitochondrial respiration due to interference of complex I in the electron transport chain being found in Parkinson’s patients. Alpha-synuclein increases fragmentation …
Functional Characterization Of Infectious Hematopoietic Necrosis Virus Matrix Protein In Host Cellular Responses, Jeffery Ringiesn
Functional Characterization Of Infectious Hematopoietic Necrosis Virus Matrix Protein In Host Cellular Responses, Jeffery Ringiesn
Browse all Theses and Dissertations
Infectious hematopoietic necrosis virus (IHNV) is a deadly fish pathogen that poses a global threat to aquatic ecosystems and the aquaculture industry. For decades, research has focused on developing vaccine therapeutics utilizing a variety of techniques and strategies. While these studies have met with some success in identifying potential vaccine targets that provided protective immunity, a commercially viable IHNV vaccine is currently unavailable. Here we explore the relationship between the structure and function of the IHNV matrix (M) protein through the introduction of mutations that reduce anti-host effects, with the goal of developing a novel recombinant IHNV with reduced pathogenicity …